JP6479029B2 - ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 - Google Patents

ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 Download PDF

Info

Publication number
JP6479029B2
JP6479029B2 JP2016550483A JP2016550483A JP6479029B2 JP 6479029 B2 JP6479029 B2 JP 6479029B2 JP 2016550483 A JP2016550483 A JP 2016550483A JP 2016550483 A JP2016550483 A JP 2016550483A JP 6479029 B2 JP6479029 B2 JP 6479029B2
Authority
JP
Japan
Prior art keywords
mmol
carboxylate
compound according
tert
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016550483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505323A (ja
Inventor
ブラウン，ジャイルズ・アルバート
キャンズフィールド，ジュリー・エレイン
コングリーヴ，マイルズ・スチュアート
オブライエン，マイケル・アリスター
ピックワース，マーク
ラッカム，マーク・デーヴィッド
テハン，ベンジャミン・ジェラルド
テオボールド，バリー・ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52465550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6479029(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1402013.5A external-priority patent/GB201402013D0/en
Priority claimed from GBGB1416622.7A external-priority patent/GB201416622D0/en
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of JP2017505323A publication Critical patent/JP2017505323A/ja
Application granted granted Critical
Publication of JP6479029B2 publication Critical patent/JP6479029B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
JP2016550483A 2014-02-06 2015-02-06 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 Active JP6479029B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1402013.5 2014-02-06
GBGB1402013.5A GB201402013D0 (en) 2014-02-06 2014-02-06 Pharmaceutical compounds
GBGB1416622.7A GB201416622D0 (en) 2014-09-19 2014-09-19 Pharmaceutical compounds
GB1416622.7 2014-09-19
PCT/GB2015/050331 WO2015118342A1 (en) 2014-02-06 2015-02-06 Bicyclic aza compounds as muscarinic m1 receptor agonists.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019017086A Division JP6774513B2 (ja) 2014-02-06 2019-02-01 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Publications (2)

Publication Number Publication Date
JP2017505323A JP2017505323A (ja) 2017-02-16
JP6479029B2 true JP6479029B2 (ja) 2019-03-06

Family

ID=52465550

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2016550483A Active JP6479029B2 (ja) 2014-02-06 2015-02-06 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2019017086A Active JP6774513B2 (ja) 2014-02-06 2019-02-01 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2020168341A Withdrawn JP2021006571A (ja) 2014-02-06 2020-10-05 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023060030A Active JP7652829B2 (ja) 2014-02-06 2023-04-03 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023076024A Active JP7652832B2 (ja) 2014-02-06 2023-05-02 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023076025A Active JP7652833B2 (ja) 2014-02-06 2023-05-02 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2025041135A Pending JP2025085736A (ja) 2014-02-06 2025-03-14 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2019017086A Active JP6774513B2 (ja) 2014-02-06 2019-02-01 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2020168341A Withdrawn JP2021006571A (ja) 2014-02-06 2020-10-05 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023060030A Active JP7652829B2 (ja) 2014-02-06 2023-04-03 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023076024A Active JP7652832B2 (ja) 2014-02-06 2023-05-02 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023076025A Active JP7652833B2 (ja) 2014-02-06 2023-05-02 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2025041135A Pending JP2025085736A (ja) 2014-02-06 2025-03-14 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Country Status (30)

Country Link
US (6) US9670183B2 (enExample)
EP (3) EP3406609B1 (enExample)
JP (7) JP6479029B2 (enExample)
KR (1) KR102352388B1 (enExample)
CN (2) CN106458986B (enExample)
AU (3) AU2015213900B2 (enExample)
BR (1) BR112016017979B1 (enExample)
CA (1) CA2938169C (enExample)
CL (1) CL2016001983A1 (enExample)
CY (1) CY1120834T1 (enExample)
DK (2) DK3102568T3 (enExample)
ES (2) ES2688548T3 (enExample)
FI (1) FI3406609T3 (enExample)
HR (2) HRP20181499T1 (enExample)
HU (1) HUE068301T2 (enExample)
IL (1) IL247117B (enExample)
LT (2) LT3406609T (enExample)
MX (2) MX393637B (enExample)
NZ (1) NZ723103A (enExample)
PH (1) PH12016501570A1 (enExample)
PL (2) PL3102568T3 (enExample)
PT (2) PT3406609T (enExample)
RS (2) RS57843B1 (enExample)
RU (1) RU2685230C2 (enExample)
SA (1) SA516371614B1 (enExample)
SG (1) SG11201606269WA (enExample)
SI (2) SI3102568T1 (enExample)
SM (1) SMT202400446T1 (enExample)
UA (1) UA122121C2 (enExample)
WO (1) WO2015118342A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019077725A (ja) * 2014-02-06 2019-05-23 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014KN01075A (enExample) 2011-11-18 2015-10-09 Heptares Therapeutics Ltd
CN110101699A (zh) 2013-03-15 2019-08-09 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
CN106687445A (zh) 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
KR102824411B1 (ko) 2015-02-27 2025-06-23 베르선 코포레이션 세린 프로테아제 저해제로서의 치환된 피라졸 화합물
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201726675A (zh) 2015-12-23 2017-08-01 默沙東藥廠 M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
PL3478679T3 (pl) 2016-07-01 2021-10-25 Pfizer Inc. Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
US11274100B2 (en) 2017-06-21 2022-03-15 Daiichi Sankyo Company, Limited EP300/CREBBP inhibitor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
CN110944999A (zh) * 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
US10501483B2 (en) 2017-10-24 2019-12-10 Allergan, Inc. Enamines and diastereo-selective reduction of enamines
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
DK3768669T3 (da) 2018-03-23 2023-04-24 Pfizer Piperazinazaspiroderivater
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
JOP20220082A1 (ar) 2019-10-09 2023-01-30 Novartis Ag مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
CR20220153A (es) * 2019-10-09 2022-05-03 Novartis Ag Derivados de 2–azaespiro [3.4] octano como agonistas de m4
ES2983860T3 (es) 2019-12-06 2024-10-25 Neurocrine Biosciences Inc Antagonistas del receptor muscarínico 4 y métodos de uso
CN115362156A (zh) * 2020-02-05 2022-11-18 纽罗克里生物科学有限公司 毒蕈碱性受体4拮抗剂及使用方法
US11912705B2 (en) * 2020-08-20 2024-02-27 The Corporation Of Mercer University Cathinone derivatives, pharmaceutical formulations, and methods
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
HRP20251427T1 (hr) 2022-08-04 2025-12-19 Nxera Pharma Uk Limited Oblici citratne soli agonista muskarinskih receptora
AU2023341169A1 (en) * 2022-09-16 2025-03-13 Cerevel Therapeutics, Llc M4 activators/modulators and uses thereof
KR20250133755A (ko) * 2023-01-12 2025-09-08 세레벨 쎄라퓨틱스, 엘엘씨 M4 활성제/조절제로서의 스피로 유도체 및 이의 용도
WO2024158645A1 (en) * 2023-01-24 2024-08-02 Neurocrine Biosciences, Inc. Deuterated compounds
CN116496195A (zh) * 2023-05-10 2023-07-28 南京优氟医药科技有限公司 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法
WO2025030095A1 (en) 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
AU2206699A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CA2444595A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
MXPA06013842A (es) * 2004-05-28 2007-03-01 Vertex Pharma Moduladores de receptores muscarinicos.
EP1863490A2 (en) * 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muscarinic modulators
KR20080087841A (ko) 2005-12-22 2008-10-01 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체의 조절제
CA2642649A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2643320A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
BRPI0708524A2 (pt) * 2006-03-03 2011-05-31 Novartis Ag compostos de n-formil hidroxilamina
GB0706188D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
MX2011004340A (es) 2008-10-29 2011-05-23 Gruenenthal Gmbh Espiroaminas sustituidas.
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2012020813A1 (ja) * 2010-08-10 2012-02-16 大日本住友製薬株式会社 縮環ピロリジン誘導体
IN2014KN01075A (enExample) * 2011-11-18 2015-10-09 Heptares Therapeutics Ltd
JP6204476B2 (ja) 2012-09-18 2017-09-27 ヘプタレス セラピューティックス リミテッド ムスカリンｍ１受容体作動薬としての二環式アザ化合物
ES2717680T3 (es) 2013-04-30 2019-06-24 Glaxosmithkline Ip No 2 Ltd Potenciador de inhibidores del homólogo de Zeste 2
EA035848B1 (ru) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
CA2945693C (en) 2014-02-06 2020-06-16 Riboscience Llc 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
FI3406609T3 (fi) 2014-02-06 2024-09-10 Nxera Pharma Uk Ltd Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
AP2017009803A0 (en) 2014-09-19 2017-03-31 Bayer Pharma AG Benzyl substituted indazoles as bub1 inhibitors
CN111909130B (zh) 2014-09-19 2023-10-31 福马治疗股份有限公司 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物
CN106687456B (zh) 2014-09-19 2019-12-03 葛兰素史密斯克莱知识产权发展有限公司 可溶性鸟苷酸环化酶活化剂及它们的用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019077725A (ja) * 2014-02-06 2019-05-23 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2021006571A (ja) * 2014-02-06 2021-01-21 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP7652833B2 (ja) 2014-02-06 2025-03-27 ネクセラ・ファーマ・ユーケイ・リミテッド ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP7652832B2 (ja) 2014-02-06 2025-03-27 ネクセラ・ファーマ・ユーケイ・リミテッド ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP7652829B2 (ja) 2014-02-06 2025-03-27 ネクセラ・ファーマ・ユーケイ・リミテッド ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Also Published As

Publication number Publication date
SG11201606269WA (en) 2016-09-29
IL247117B (en) 2021-03-25
JP2021006571A (ja) 2021-01-21
PH12016501570B1 (en) 2016-10-03
EP3102568A1 (en) 2016-12-14
LT3102568T (lt) 2018-11-12
MX2016010322A (es) 2017-04-27
WO2015118342A1 (en) 2015-08-13
DK3102568T3 (en) 2018-10-08
RU2016133684A (ru) 2018-03-14
NZ723103A (en) 2022-09-30
US20190112294A1 (en) 2019-04-18
LT3406609T (lt) 2024-09-25
US9670183B2 (en) 2017-06-06
RS57843B1 (sr) 2018-12-31
MX2020001236A (es) 2022-06-30
EP3406609A1 (en) 2018-11-28
ES2986327T3 (es) 2024-11-11
PT3102568T (pt) 2018-10-24
SI3102568T1 (sl) 2018-11-30
JP7652833B2 (ja) 2025-03-27
CN106458986A (zh) 2017-02-22
AU2019201579A1 (en) 2019-03-28
ES2688548T3 (es) 2018-11-05
JP2023073504A (ja) 2023-05-25
AU2015213900A1 (en) 2016-08-11
US10196380B2 (en) 2019-02-05
EP4413985A3 (en) 2024-10-23
US20170015650A1 (en) 2017-01-19
KR20160129014A (ko) 2016-11-08
AU2020277225A1 (en) 2020-12-24
SMT202400446T1 (it) 2024-11-15
RU2016133684A3 (enExample) 2018-08-31
JP2025085736A (ja) 2025-06-05
AU2019201579B2 (en) 2020-08-27
HRP20241145T1 (hr) 2024-11-22
JP2019077725A (ja) 2019-05-23
HUE068301T2 (hu) 2024-12-28
SI3406609T1 (sl) 2024-10-30
CL2016001983A1 (es) 2017-06-23
KR102352388B1 (ko) 2022-01-17
MX371529B (es) 2020-01-31
EP4413985A2 (en) 2024-08-14
CY1120834T1 (el) 2019-12-11
JP6774513B2 (ja) 2020-10-28
JP7652832B2 (ja) 2025-03-27
MX393637B (es) 2025-03-11
JP2023087046A (ja) 2023-06-22
JP2017505323A (ja) 2017-02-16
CN106458986B (zh) 2019-01-04
FI3406609T3 (fi) 2024-09-10
CN109851610B (zh) 2021-09-21
JP7652829B2 (ja) 2025-03-27
AU2015213900B2 (en) 2018-12-13
HK1231473A1 (en) 2017-12-22
US20180179184A1 (en) 2018-06-28
BR112016017979A2 (enExample) 2017-08-08
PL3406609T3 (pl) 2024-11-25
SA516371614B1 (ar) 2019-10-30
RS65894B1 (sr) 2024-09-30
UA122121C2 (uk) 2020-09-25
EP3406609B1 (en) 2024-06-26
US9926297B2 (en) 2018-03-27
US10385039B2 (en) 2019-08-20
PH12016501570A1 (en) 2016-10-03
HRP20181499T1 (hr) 2018-11-30
IL247117A0 (en) 2016-09-29
RU2685230C2 (ru) 2019-04-17
CA2938169A1 (en) 2015-08-13
EP3102568B1 (en) 2018-06-27
CN109851610A (zh) 2019-06-07
BR112016017979B1 (pt) 2022-08-02
CA2938169C (en) 2022-03-15
WO2015118342A8 (en) 2016-06-30
US20170240530A1 (en) 2017-08-24
PT3406609T (pt) 2024-09-17
DK3406609T3 (da) 2024-08-26
US20200325118A1 (en) 2020-10-15
US10689368B2 (en) 2020-06-23
PL3102568T3 (pl) 2019-01-31
JP2023087045A (ja) 2023-06-22
US20190337925A1 (en) 2019-11-07
US10961225B2 (en) 2021-03-30

Similar Documents

Publication Publication Date Title
JP7652833B2 (ja) ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
RU2811601C1 (ru) Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
RU2811601C9 (ru) Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
HK40114593A (en) Pharmaceutical compounds
HK40007500A (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
HK40007500B (zh) 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物
HK1231473B (en) Bicyclic aza compounds as muscarinic m1 receptor agonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180831

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190205

R150 Certificate of patent or registration of utility model

Ref document number: 6479029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157